U.K. agency suggests restriction on use of drug-eluting stents

09/24/2008 | FDAnews

The use of drug-eluting stents should be limited to coronary-artery disease patients who would likely require future interventions if they received a conventional bare-metal stent instead, according to a final guidance from the U.K.'s National Institute for Health and Clinical Excellence. NICE's final guidance offers data on specific drug-coated stents and their individual prices.

View Full Article in:

FDAnews

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
Catheter Engineer
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
MANAGER MEDICAL GAS COMPLIANCE AND SAFETY
Matheson Tri-Gas, Inc.
Houston, TX
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations